China allows AstraZeneca's COVID preventive drug in southern city

AstraZeneca Plc's antibody cocktail for COVID-19 prevention has been cleared for use in a medical tourism zone in China's southern province of Hainan ahead of national approval, local media said on Tuesday. China allows early use of new medical products in the special zone in Qionghai city as a part of several preferential policies granted to the area to promote medical services to visitors from both home and abroad.